MCKESSON CORP

McKesson’s pivot to digital health—leveraging its pharma logistics with AI‑powered RPM, CDSS, and data‑broker services—offers a 33% digital revenue boost amid rising regulatory and competitive challenges.

CEO Tyler Brian S. bought 12.5 M McKesson shares via a 10(b)(5) plan, adding to 10 M shares in the company’s 401(k) – a compliance‑focused SEC filing that shows executive confidence but not strategic change.

McKesson’s June 2026 SEC filings reveal stable executive ownership, compliant RSU grants and modest share‑price growth, underscoring its conservative equity strategy.

Explore how MCKESSON CORP’s minor weighting in Munro‑managed ETFs influences portfolio dynamics and investor insights.

McKesson’s May 2026 filings show executive RSU sales and Rule 144 compliance, highlighting strong governance, shareholder alignment, and transparency for investors and healthcare stakeholders.

McKesson Corp’s hospitality division sees 15% RevPAR gains, 7.2% occupancy rise, and cost cuts via smart refurbishments—boosting profits while keeping leverage low.

McKesson’s May 2026 insider trades show CEO and CFO block purchases backed by multi‑year PSUs, revealing a strategic blend of ownership, long‑term incentives and market‑aligned governance.

McKesson’s 10‑year stock surge shows how robust pharma distribution boosts investor returns and improves drug safety, efficacy, and access for patients.

McKesson’s Q4 earnings reveal rising specialty‑drug revenues, supply‑chain resilience, and a bright outlook—insights that shape healthcare distribution and investor sentiment.

McKesson Corp. shares dip after all‑time high—technical analysis shows a likely short‑term pullback, seasonal patterns and diversified fund exposure suggest a brief consolidation rather than a lasting reversal.